Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-EGFRvIII CAR T Cells for Malignant Gliomas
NCT01454596Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- May 2012
- Primary completion
- Nov 2018
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
A Phase 2 trial of anti-EGFRvIII CAR-T cells in malignant glioma, glioblastoma (GBM), Gliosarcoma (GS), sponsored by National Cancer Institute. Started May 2012; status: completed.
02
Drugs
anti-EGFRvIII CAR-T cells
03
Conditions
malignant gliomaglioblastoma (GBM)Gliosarcoma (GS)
Beyond the preview
Go deeper on NCT01454596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01454596.